Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Sponsor
Bayer
Study ID
NCT02425501
Status
Completed

Conditions

  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objectives of this study are to investigate the safety and effectiveness of EYLEA

Key Dates

Start date
Jan 20, 2015
Status verified
Jan 2023
Primary completion
Apr 26, 2019
Completion
Aug 13, 2019

Study Design

Enrollment
646 participants (actual)

Arms

  • Arm: Aflibercept (Eylea,BAY86-5321)
    Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert

Primary Outcome Measure

Number of participants of Adverse Events [ Time Frame: Up to 12 months ]

Related Studies